Stimulated cells and cancer cells have widespread shortening of mRNA 3'-utranslated regions (3'UTRs) and switches to shorter mRNA isoforms due to usage of more proximal polyadenylation signals (PASs) in the last exon and in introns. U1 snRNA (U1), vertebrates' most abundant non-coding (spliceosomal) small nuclear RNA, silences proximal PASs and its inhibition with antisense morpholino oligonucleotides (U1 AMO) triggers widespread mRNA shortening. Here we show that U1 AMO also modulates cancer cells' phenotype, dose-dependently increasing migration and invasion in vitro by up to 500%, whereas U1 over-expression has the opposite effect. In addition to 3'UTR length, numerous transcriptome changes that could contribute to this phenotype are observed, including alternative splicing, and mRNA expression levels of proto-oncogenes and tumor suppressors. These findings reveal an unexpected link between U1 regulation and oncogenic and activated cell states, and suggest U1 as a potential target for their modulation.
Introduction
Widespread shortening of mRNA 3'-utranslated regions (3'UTRs) and switches to short mRNA isoforms is a common feature and contributing factor to cell stimulation, seen in immune cells and neurons, and oncogenicity [1] [2] [3] [4] [5] [6] . These shortening events occur due to a shift in usage of more upstream polyadenylation signals (PASs) in the last exon and in introns. In quiescent cells, these PASs are generally silenced by U1 snRNP (U1), vertebrates' most abundant non-coding small nuclear RNP, which is necessary for production of full-length RNA polymerase II transcripts from protein-coding genes and long noncoding RNAs 7 . This U1 activity, called telescripting, requires RNA base-pairing of U1 snRNA 5'-end, which is also required for U1's role in 5' splice site (5'ss) recognition.
U1 antisense morpholino oligonucleotides (U1 AMO), which inhibits U1:pre-mRNA basepairing, triggers widespread premature cleavage and polyadenylation (PCPA) as well as inhibits splicing 8, 9 . Transfection of a high U1 AMO dose that masks all, or nearly all, of U1 snRNA 5'-end causes drastic PCPA from cryptic PASs frequently found in the 5'-side of the intron in pre-mRNAs of thousands of genes 8, 9 , especially in long introns of large genes (>39kb). In contrast, small genes (<6.8kb) are generally PCPA-resistant and many of them are up-regulated in this environment. Importantly, these small genes are enriched in functions related to cell survival and acute cell stress response 7 . The drastic PCPA from high U1 AMO in many genes obscures other effects that are more readily detected with low U1 AMO doses. These changes include 3'UTR shortening (shifts to usage of more proximal PASs in tandem PASs) and the production of shorter mRNA isoforms from PAS usage in introns 9 . This revealed that low U1 AMO recapitulates known shifts to shorter mRNA isoforms that occurs in stimulated neuronal cells. We have shown previously that the stimulation-induced rapid transcription up-regulation creates transient telescripting deficit because U1 levels cannot rise in step with the transcription surge from immediate early genes 9 . U1 synthesis is a slower process involving nuclear export of pre-snRNAs, SMN complex-mediated snRNP assembly in the cytoplasm, and re-import to the nucleus 10 . Consequently, some pre-mRNAs transcribed in this time window (~2-6 hours post stimulation) are processed to shorter mRNA isoforms due to PCPA in introns.
For example, pre-mRNA processing of homer-1, which encodes a synaptogenesis scaffold protein, shifted from full-length mRNA to a shorter mRNA isoform that encodes antagonistic activity due to PCPA in an intron 11 . Importantly, low U1 AMO recapitulated the same isoform switching 9 . Here, we investigated if low U1 AMO could also modulate cell phenotype.
Results and Discussion

U1 level changes modulate hallmark phenotypes of cancer cells in vitro
We used standard in vitro assays to determine if moderate U1 inhibition has an effect on proliferation, migration, or invasion of cancer cells, which serve as quantitative measures of oncogenic phenotype. Various low U1 AMO doses (2.5 ~ 250 pmole) or control, non-targeting AMO (cAMO) were transfected into HeLa cells, a cervical carcinoma cell line ( Fig. 1 ). These U1 AMO doses masked ~15-30% of U1 snRNA 5'ends, making it inaccessible for base-pairing corresponding to the U1 AMO dose 8, 9 . As shown in Fig. 1a , 62.5 pmole U1 AMO moderately increased (38%) cell proliferation after 48-72 hours. Higher U1 AMO doses (³250 pmole) were toxic and reduced overall cell numbers. Remarkably, low U1 AMO dose-dependently enhanced cell migration and invasion by up to ~500% in 24 hours with peak activity at 62.5 pmole ( Fig. 1b-e ). The increased migration and invasion reflect true enhancements that could not be accounted for by the comparatively small increase in cell number (Fig. 1a ). U2 AMO, which interferes with U2 snRNP's function in splicing 12 , did not enhance any of these phenotypes over the entire dose range, indicating that the specificity of the U1 AMO effects ( Supplementary   Fig. 1 ).
To further examine the effects of U1 on cell phenotype, we over-expressed U1 (U1 OE) from a plasmid carrying U1 snRNA gene with its native promoter and termination elements. This achieved 20% and 40% U1 level increases compared to empty plasmid by transfecting 1µg and 1.5µg of this plasmid, respectively ( Supplementary Fig. 2 ). The U1 OE significantly and dose-dependently attenuated cell migration (25-50%) and cell invasion (25-65%) after 24 hours ( Table 1 ). Conversely, U1 OE attenuated the migration and invasion of these cell lines by ~50% compared to the control levels ( Supplementary Table 1 ).
U1 level changes cause numerous and diverse transcriptome changes
We used high-throughput RNA sequencing (RNA-seq) to determine transcriptome changes resulting from U1 level modulation. To enhance detection of nascent RNAs, as U1 functions co-transcriptionally 7 ,we metabolically labeled RNAs with 4-thiouridine (4-shU) for two hours (at 6-8 hours post-transfection with AMOs and 22-24 hours of U1 OE), and sequenced the thiol-selected RNAs. Reads were mapped to the human genome (UCSC, hg38) and filtered for unique alignments. The statistics of the RNA-seq datasets, normalized for sequencing depth as reads per million (RPM), are shown in Supplementary Table 3 . Frequently, more than one type of change was detected in transcripts of the same gene (18-47%; Supplementary Fig. 3 ). Generally, the number of events for each type of change increased with U1 AMO dose and there was extensive overlap (31-97%) between events detected at the two doses tested (Supplementary Table 3 ).
Confirming earlier observations from datasets with lower resolution and sequencing depth 9 , low U1 AMO elicited widespread 3'UTR shortening readily detected in genome browser views, for example, TOP2A, TFRC and CDC25A. (Fig. 3) . A common approach to identify changes in locations of 3'-poly(A)s is to use oligo(dT)-primed RNAseq 13 . However, it is not quantitative and does not provide adequate information on overall transcriptome changes due to 3' bias. An alternative method, DaPars, uses a regression model to deduce alternative PAS usage among multiple tandem 3'UTR PASs from standard RNA-seq 14 . Frequently, 3'UTRs have multiple tandem PASs, resulting in complex mixtures of mRNAs with various 3'UTR lengths that make it difficult to resolve by DaPars. We reasoned that a shift in usage to proximal 3'UTR PASs would decrease the overall amount of transcription in the 3'UTR, while a shift to more distal PASs will increase it. As changes in 3'UTR amount could result from mRNA expression level changes alone, we calculated the ratio of RNA-seq reads in the 3'UTR to the reads in the portion of the CDS in the same last exon (heretofore LECDS). This normalizes 3'UTR signal to mRNA expression. A decrease or increase in LECDS in a sample compared to control suggests 3'UTR shortening or lengthening, respectively. LECDS identified 3'UTR shortening in 1,919 genes in both 12.5 and 62.5 U1 AMO (p £ 0.01), and only a small fraction (130 genes) had more reads in 3'UTRs ( Fig. 3a) . In contrast, U1 OE caused a 3' increase in reads (longer 3'UTRs) in 3,210 mRNAs, while it shortened 3'UTRs in only 344 genes (Fig. 3b ). The large overlap of the lengthened (~84%) and shortened genes (~76%) in both U1 OE (1µg and 1.5µg) and U1 AMO samples (U1 AMO 12.5 and 62.5), respectively, showed a strong validation of the RNAseq data from separate biological experiments. Comparison of the 3'UTR changes identified using LECDS to those identified using DaPars showed an overlap of 79% in the samples. Moreover, LECDS identified 2,630 more events than DaPars ( Supplementary   Fig. 4 ), which is likely due to increase usage at multiple PASs rather than a strong increase in usage of a single alternative PAS. Further confirmation of 3'UTR shortening and lengthening is shown for select examples in Fig. 3c-d , and 3'RACE validation data are presented in Supplementary Fig. 5 . Notably, the fraction of genes that had 3'UTR length changes corresponded to the U1 AMO or OE dose, and U1 OE caused transcription in some genes to extend farther downstream from canonical gene ends.
Thus, U1 has a role in regulation of both proximal and distal PASs.
As expected for U1's role in splicing, U1 AMO caused alternative splicing (AS) changes in ~700 genes, including A5'SS and A3'SS, cassette exon (CE) and intron retention (IR) events (Supplementary Table 3 Supplementary Fig. 8 ) [17] [18] [19] [20] .
U1 level changes alters expression of cancer genes
To explore the potential role of U1 dependent 3'UTR length changes on the oncogenic phenotype we observed, we interrogated our gene set against cancer gene databases [Sanger 21 and UCSF (waldman.ucsf.edu/GENES/completechroms.html)].
These archives include oncogenes induced through various mechanisms, including mutation, chromosomal translocation, or loss of miRNA repression, and the analysis revealed that a large number of oncogenes incurred 3'UTR length changes. The oncogenes affected at each U1 level, 204 in total, are listed in Supplementary Table 4 and include cell cycle regulation (CDC25A, CCNB1), apoptosis (BCL6, BRCA1), cell migration (FGFR1, FYN), extracellular matrix remodeling (TIMP2), signaling (EGFR), transcription (WNT5A), metastasis and tumor progression (EWSR1, APC, BRAF).
There are numerous examples of cancers resulting from oncogene up-regulation due to loss of miRNA repression, either because the relevant miRNA is down-regulated or its target in the 3'UTR has been removed 22-25 . U1 level changes recapitulated the same miRNA 3'UTR target elimination or restoration in many genes ( Fig. 3c-d ). For CDC25A, an essential phosphatase for the G1-S transition, 3'UTR shortening eliminates several miRNA-binding sites including let-7, miR-15 and miR-21 ( Fig. 3c ). An increase in CDC25A protein due to alleviation of miRNA-mediated repression exacerbates hepatic cyst formation and colon cancer 26-28 . 3'UTR shortening in RAS oncogene family member, RAB10, which removes target sites for miRs-103/107, is found in numerous cancer cell lines and results in a dramatic increase of this protein 4 . As shown in Fig. 3d, 3 'UTR of RAB10 is already shortened in HeLa cells, and U1 OE reverses this shortening and restores the corresponding miRNA binding sites. Similarly, U1 OE lengthened 3'UTR of KRAS to include a let-7 binding site ( Fig. 3d ). This region contains a polymorphism that has been shown to impair let-7 binding, and is prognostic for breast cancer aggressiveness 29 . U1 AMO also did not change the associated miRNA expression ( Supplementary Fig. 9 ). In addition to loss or gain of miRNA-binding sites, 3'UTR length or amount changes can affect other mRNA regulating elements, such as AU-rich elements (AREs), with roles in cancer phenotype. For example, U1 OE-induced 3'UTR lengthening in c-Fos, a gene controlling cell proliferation, differentiation, survival and tumorigenesis 30,31 , restores an ARE and strongly decreases mRNA level (>2-fold, data not shown).
Several other factors that can regulate 3'UTR length have been described, particularly components of the cleavage and polyadenylation machinery (CPA) 13, [32] [33] [34] [35] [36] .
Knockdown of CPSF6/CFIm68, CPSF5/CFIm25, and PABPN1 cause widespread 3'UTR shortening 35, 37, 38 . Furthermore, CPSF5 and CPSF6 are down-regulated in cancers and their knockdowns in cell lines enhances oncogenicity 14, 35, 39, 40 . It is possible that these CPA factors work in concert with U1. 3' UTR shortening analysis of the RNA-seq of CPSF5 knockdown in HeLa cells by LECDS identified 1,210 genes (63% overlap with U1 AMO) that are also shortened in U1 AMO (Supplemental Fig. 10 ), suggesting potentially extensive commonality of targets. A recent study described that U1 over-expression in PC-12 rat neuronal cell line up-regulated cancer related genes, including MYC and FOS 41 . While these results appear to be inconsistent with our observations, they may be explained by the different cell types used in these studies and by different U1 levels relative to transcription.
The large number and diversity of transcriptome changes make it impossible to attribute the phenotypic change to specific transcriptome changes. However, many of the changes could be oncogenic by themselves. Thus, a surprising overall observation is that at normal U1 and transcription levels, U1 snRNP has a tumor suppressor-like function.
U1's ability to regulate such genes, and loss of these functions as less U1 is available, fulfills the definition of (an overarching) tumor suppressor 42, 43 . Mutations in several splicing factors, particularly U2-associated factors and SR proteins, have been shown to drive many cancers 17, 18 . However, the potential role of U1 in cancer has not been tested previously. Our findings demonstrate that U1 homeostasis is necessary for maintaining normal expression of many of the same factors, as well as numerous other cancer-related genes. In this vein, it is intriguing that the major U1 gene cluster in humans at chr1p36.13 flanks a breakpoint linked to many cancers 44 . The potential effect of these genomic abnormalities on U1 levels remains to be determined. Mounting evidence indicate that U1 AMO and U1 over-expression mimic biological processes 7, 9, [45] [46] [47] [48] . Thus, these experimental tools for dose-dependent modulation of U1 should facilitate studies on cancer and stimulated cells behavior, and suggest U1 as a potential clinical target for a wide range of disorders.
Methods
Cell culture and treatment. Cells (HeLa, A549, MCF-7 and MB-231) were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 10 units/ml penicillin and 10 μg/ml streptomycin at 37°C and 5% CO2. U1, U2 antisense and control morpholino oligonucleotide sequences were as previously described 8 
Migration and invasion assays.
For migration studies, a standard assay was used to determine the number of cells that traversed a porous polycarbonate membrane in response to a chemo-attractant (higher serum concentration) 49, 50 using the Cytoselect 24well cell migration assay (Cell Biolabs). Invasion was measured using BD BioCoat Matrigel invasion chambers (BD Bioscience). In both assays, cells were transfected with AMOs, and 1.5 x 10 5 and 2.5 x 10 5 cells per well were seeded in an upper chamber in serum free media for the migration and invasion assay, respectively. The lower chamber was filled with media containing 10% FBS. After 24 hours, cells passing through polycarbonate membrane were stained and counted according to the manufacturer's instructions.
Metabolic RNA labeling, isolation and RNA-seq. 4 Spliced Isoform). Significant differential alternative splicing events were detected by performing a Χ 2 likelihood-ratio test followed by Benjamini-Hochberg (BH) multiple testing with an adjusted P-value ≤ 0.01. For stringent inclusion, we also restricted ∆PSI >=10%.
TargetScan miRNA regulatory sites were downloaded from UCSC Genome browser (http://genome.ucsc.edu/). The coordinate of each predicted miRNA site was compared to those genes for which the 3'UTR showed changes in length. For miRNA microarray, HeLa cells were transfected with control or 62.5 pmole U1 AMO for 8 hours. Total RNA was extracted using miRNeasy kit (Qiagen) according to manufacturer recommendations. 
